Department of Medicine, Hematology Institute, Meir Medical Center, Kfar Saba, Israel.
Hematol Oncol Clin North Am. 2011 Apr;25(2):277-91, vii. doi: 10.1016/j.hoc.2011.01.001.
Treatment of pregnant women with chemotherapy may pose a risk to the fetus, raising therapeutic, ethical, moral, and social dilemmas. Publications on this issue are limited to retrospective series and case reports, thus further complicating decision making. Diagnosis and staging are usually performed as in nonpregnant women, but procedures that expose the fetus to radiation are excluded. Chemotherapy is not recommended in the first trimester to avoid fetal malformations. Thus, the option is either treatment delay or pregnancy termination. Later in pregnancy, treatment is often initiated without delay, with no apparent evidence of teratogenicity.
对孕妇进行化疗可能会对胎儿造成风险，引发治疗、伦理、道德和社会方面的困境。关于这个问题的出版物仅限于回顾性系列和病例报告，这使得决策更加复杂。诊断和分期通常与非孕妇相同，但会排除使胎儿暴露于辐射的程序。为避免胎儿畸形，不建议在孕早期进行化疗。因此，选择要么是延迟治疗，要么是终止妊娠。在妊娠后期，通常会毫不犹豫地开始治疗，没有明显的致畸证据。
